诺和诺德裁员9000人并削减早期管线;强生抑郁症疗法获批一周缓解抑郁;赛诺菲可倍力在华获批罕见病aTTP迎靶向疗法

药财社
Nov 07, 2025

●药闻快报▲关注药财社聚焦医药界▲1诺和诺德裁员9000人并削减早期管线诺和诺德正在逐步终止一系列肝病、肿瘤学和干细胞的早期项目。在诺和诺德发布的第三季度财报中,公司宣布因大规模重组计划而提高达90亿丹麦克朗(约合14亿美元)的支出,其中包括全球裁员约9000人,以及彻底关闭细胞疗法研发部门。此次被砍的细胞疗法项目涵盖帕金森病、慢性心力衰竭,以及旨在逆转或治愈1型糖尿病的研究。公司也确认,已彻底...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10